A 2026 systematic review pulled together every published study on GLP-1 receptor agonists and male reproductive hormones. Across 10 studies and 639 men, the pattern was consistent: weight-loss drugs like semaglutide and tirzepatide raise testosterone in obese men -- and unlike testosterone replacement, they preserve fertility.
This is not a weight-loss-drug commercial. It is a serious shift in how men with obesity-related low testosterone should think about treatment. For roughly half of men with low T who are also overweight, the cause is metabolic suppression -- not testicular failure. Fix the metabolism and the hormones often follow.
Key Takeaways
- 2026 systematic review of 639 men: GLP-1s consistently raise testosterone in obese and diabetic men
- Roughly 1 nmol/L (29 ng/dL) total testosterone gain per 5 kg of weight loss
- In one cohort, men with normal total and free testosterone rose from 53 percent to 77 percent
- Unlike TRT, GLP-1s preserve LH, FSH, and sperm production
- 24-week head-to-head: semaglutide improved sperm morphology, TRT worsened sperm count
- Not for primary hypogonadism, lean men, or men whose low T is not obesity-driven
- Compare online TRT clinics that handle both metabolic and hormone care
What the 2026 Review Actually Found
The systematic review, published in The Journal of Sexual Medicine, evaluated 10 studies covering 639 men treated with GLP-1 receptor agonists -- semaglutide, dulaglutide, liraglutide, and tirzepatide. The methodology pulled together randomized trials, retrospective cohorts, and prospective observational studies.
The signal was directionally consistent across study types. GLP-1 use was associated with:
- Higher total testosterone, especially in men with obesity, type 2 diabetes, or functional hypogonadism
- Preserved or increased LH and FSH -- the gonadotropins that drive testicular function
- Improved or stable semen parameters in studies that measured them
- Roughly 1 nmol/L total testosterone gain per 5 kg lost, mirroring older bariatric surgery data
The contrast with TRT is the key finding. Testosterone replacement raises serum testosterone but suppresses LH and FSH through negative feedback at the hypothalamus and pituitary. The testes shrink. Sperm production crashes. GLP-1s do the opposite -- they release the metabolic brake on the HPG axis, and the testes resume normal output.
The Cohort Data Most Men Will Care About
A separate 2025 retrospective electronic health record analysis presented at the Endocrine Society annual meeting included 110 men with obesity or type 2 diabetes started on semaglutide, dulaglutide, or tirzepatide. Over 18 months:
- Average weight loss: about 10 percent of body weight
- Proportion with normal total and free testosterone: 53 percent at baseline -> 77 percent at follow-up
- Effect held across all three drugs, suggesting it is the weight loss, not a direct GLP-1 receptor effect on the testes
That is a 24 percentage-point gain in men reaching the normal range without ever touching exogenous testosterone. For men who got pushed toward TRT because their levels came back low on a standard panel, this matters.
Why This Works -- The Mechanism
Obesity does not just correlate with low testosterone. It causes it. Three overlapping pathways suppress the HPG axis:
Aromatization. Adipose tissue contains aromatase, the enzyme that converts testosterone to estradiol. More fat means more aromatization, which means lower testosterone and higher estradiol. The estradiol then suppresses LH at the pituitary, dropping signaling to the testes.
Leptin and insulin resistance. Obese men typically have high circulating leptin and insulin, both of which become "resistant" -- the body stops responding normally to them. Leptin and insulin resistance disrupt kisspeptin signaling in the hypothalamus, which is the upstream driver of gonadotropin-releasing hormone (GnRH) pulses.
Inflammation. Chronic low-grade inflammation from visceral fat suppresses GnRH neurons directly through cytokine pathways like TNF-alpha and IL-6.
The result is functional hypogonadism: the testes work fine, but the brain is sending weak signals. Conventional TRT bypasses the broken signaling by replacing the end product (testosterone). GLP-1-driven weight loss fixes the upstream signaling problem, restoring the natural axis.
This is why the trt-vs-natural-optimization decision matters more for obese men than lean ones. If your low T is metabolic, you have an option that fixes the cause.
How GLP-1s Compare to TRT for Obesity-Related Low T
The most useful single piece of evidence is a 24-week randomized open-label trial of 25 men with type 2 diabetes, obesity, and functional hypogonadism. Half got semaglutide 1 mg weekly. Half got intramuscular testosterone undecanoate 1000 mg every 10 to 12 weeks. Endpoints included total testosterone, hypogonadism symptom scores, and detailed semen analysis.
| Outcome |
Semaglutide |
Testosterone Undecanoate |
| Total testosterone increase |
Yes (significant) |
Yes (significant, larger) |
| Hypogonadism symptom improvement |
Yes |
Yes |
| LH / FSH |
Preserved or increased |
Suppressed |
| Sperm concentration |
Stable |
Decreased |
| Total sperm number |
Stable |
Decreased |
| Sperm morphology |
Significantly improved |
No improvement / declined |
| Body weight |
Decreased |
Unchanged |
| HbA1c |
Improved |
Minimal change |
The trade-off is real. TRT raises testosterone faster and higher. GLP-1 raises testosterone more slowly but improves metabolic health, fertility markers, and weight at the same time.
For a 35-year-old obese man who wants kids in the next two years, this is not a close call. For a 60-year-old retired man who does not care about fertility, TRT may still be the better tool.
Who Should Consider a GLP-1 Instead of TRT
The decision comes down to four questions:
1. Is my low T obesity-related? If your BMI is over 30 (or over 27 with metabolic syndrome) and your LH and FSH are low or low-normal, your hypogonadism is functional. GLP-1 weight loss is likely to help.
2. Do I want to preserve fertility? TRT shuts down spermatogenesis. Recovery after stopping takes 6 to 24 months and is not guaranteed. If kids are on the table, GLP-1 plus weight loss avoids the problem entirely. See the fertility-on-TRT guide for the alternative protocol if you go the TRT route.
3. Am I willing to wait? TRT works in weeks. GLP-1-driven testosterone recovery takes 6 to 12 months because it is downstream of weight loss. If you are symptomatic and miserable now, the speed difference matters.
4. Can I tolerate GLP-1 side effects? Nausea, constipation, and reflux are common in the first 8 weeks. Most men adapt, but 10 to 15 percent stop the drug. Pancreatitis, gallbladder issues, and rare gastroparesis are real risks worth screening for.
If you answer "yes, yes, yes, yes" -- start with a GLP-1. If you answer "no" to any of those, TRT is probably still the better fit.
What About Men Who Are Not Obese?
GLP-1s are not magic. The testosterone benefit comes from fixing obesity-driven HPG axis suppression. If you are 5'10" and 175 lb with low testosterone, the cause is something else -- primary testicular failure, undiagnosed pituitary issue, opioid suppression, varicocele, or genetic. A GLP-1 will not fix any of those. You need proper lab workup including LH, FSH, prolactin, ferritin, and possibly a pituitary MRI before deciding on therapy.
How to Combine the Two -- The Sequential Protocol
Some men do not have to choose. A growing number of clinics are running a sequential protocol:
Phase 1 (months 0-12): GLP-1 alone. Maximize weight loss. Reassess testosterone and symptoms at 6 and 12 months.
Phase 2 (month 12+): If testosterone is still low and symptoms persist after substantial weight loss, add TRT at the lowest effective dose. Continue the GLP-1.
Phase 3: Once weight is stable and metabolic markers are normalized, evaluate whether TRT is still needed. Some men can taper off after 12 to 24 months on a maintained body composition.
This protocol is reasonable but it requires a clinic that actually thinks about both pathways. Many TRT clinics will start you on testosterone before they run a full workup. Many GLP-1 telehealth clinics do not measure testosterone at all. The clinics that handle both well are listed in the best online TRT clinic and best online HRT clinic for women reviews -- look specifically for ones that bundle metabolic care.
What This Means for the TRT Industry
Roughly 40 to 50 percent of men starting TRT in 2026 are overweight or obese. If even a third of those men respond to GLP-1 monotherapy, the addressable TRT market shrinks meaningfully. That is partly why several large telehealth platforms are rolling GLP-1 and testosterone services into bundled offerings -- they want the patient relationship regardless of which drug they end up on.
The flip side: for men whose hypogonadism is metabolic, this is unambiguously good news. You may have a fix that costs less long-term, preserves fertility, improves cardiovascular markers, and reverses diabetes risk. TRT does none of those things on its own.
The downside risk is that men get sold a GLP-1 when they actually have primary hypogonadism. The 6- to 12-month wait for testosterone to recover is wasted time if the underlying cause is testicular and not metabolic. This is why pre-treatment LH and FSH measurement is non-negotiable. If LH is high and testosterone is low, you have testicular failure and weight loss will not fix it. If LH is low and testosterone is low, you have functional hypogonadism and weight loss probably will.
What to Do Next
If you are obese with low T and have not yet started TRT:
- Get a full hormone panel -- total T, free T, LH, FSH, SHBG, estradiol, prolactin. See how to test testosterone properly.
- Check if your low T is functional -- if LH and FSH are low or low-normal, weight loss is likely to help.
- Talk to a clinic that handles both -- ask specifically about GLP-1 protocols for functional hypogonadism. The questions-to-ask-trt-clinic checklist helps.
- Set a 6-month checkpoint -- if you have not lost meaningful weight or testosterone has not moved, escalate to TRT (with hCG if fertility matters).
If you are already on TRT and obese:
- Do not stop TRT abruptly. That will crash your testosterone for months while your axis recovers.
- Add a GLP-1 alongside TRT -- this is increasingly common and is metabolically safe. Watch hematocrit closely.
- At 12 months on the combination, discuss tapering TRT if weight loss has been substantial and metabolic markers are normalized.
If you are lean with low T:
- GLP-1s are not your answer. Skip them.
- Push for a real workup including LH, FSH, prolactin, ferritin, and pituitary MRI if indicated.
- TRT, hCG, or enclomiphene are your main options depending on the underlying cause.
Bigger Picture
The 2026 evidence on GLP-1s and male hormones is part of a broader pattern: hormone therapy is moving from "symptomatic replacement" to "fix the underlying cause when possible." The April 2026 FDA expansion of TRT labeling for idiopathic hypogonadism goes the other way -- toward treating symptoms regardless of cause. Both can be right depending on the patient.
For the obese man with low testosterone, the question used to be: "Which TRT formulation?" The 2026 question is: "Should I be on TRT at all, or can I fix this with weight loss?" For roughly half of obese men with low T, the answer may now be the second one.
References
- Salvio G, Ferlito C, Cutini M, et al. Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review. J Sex Med. 2026. PMID: 41498523.
- Gregoric N, Groselj-Strele A, Jensterle M, et al. Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism. Diabetes Obes Metab. 2025. PMID: 39511836.
- Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829-843. PMID: 23482592.
- Calderon-Margalit R, Schwartz SM, Wellons MF, et al. Endogenous Testosterone, Testosterone Treatment, and Cardiovascular Health Outcomes in Men. J Clin Endocrinol Metab. 2026;111(2):e339-e352.
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. (TRAVERSE trial reference for TRT cardiovascular context.)
- Grossmann M, Matsumoto AM. A Perspective on Middle-Aged and Older Men with Functional Hypogonadism: Focus on Holistic Management. J Clin Endocrinol Metab. 2017;102(3):1067-1075. PMID: 28359097.
Related Reading